Is Pfizer in debt?

Understanding Pfizer's Financial Position

When evaluating the financial health of major pharmaceutical corporations, debt is a common and necessary tool used to fund large-scale operations, research, and strategic acquisitions. Like many industry leaders, Pfizer carries a significant amount of liabilities on its corporate balance sheet to maintain its competitive edge in global healthcare.

The Current Debt Figures

According to financial reports for the fiscal quarter ending in March 2026, Pfizer's total debt stands at approximately $63.73 billion USD. While this is a substantial figure in absolute terms, it must be evaluated alongside the company's massive asset portfolio, ongoing revenue streams from diverse product lines, and consistent market performance.